Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3443807rdf:typepubmed:Citationlld:pubmed
pubmed-article:3443807lifeskim:mentionsumls-concept:C0028811lld:lifeskim
pubmed-article:3443807lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:3443807lifeskim:mentionsumls-concept:C0038435lld:lifeskim
pubmed-article:3443807lifeskim:mentionsumls-concept:C1882598lld:lifeskim
pubmed-article:3443807lifeskim:mentionsumls-concept:C0011777lld:lifeskim
pubmed-article:3443807lifeskim:mentionsumls-concept:C0205245lld:lifeskim
pubmed-article:3443807lifeskim:mentionsumls-concept:C0205345lld:lifeskim
pubmed-article:3443807lifeskim:mentionsumls-concept:C0034795lld:lifeskim
pubmed-article:3443807pubmed:issue3lld:pubmed
pubmed-article:3443807pubmed:dateCreated1988-4-28lld:pubmed
pubmed-article:3443807pubmed:abstractTextThe rat brain contains two receptor systems for corticosterone: the type-I corticosterone-preferring receptor and the classical type-II glucocorticoid receptor. The two receptor populations can be distinguished in binding studies with the 'pure' synthetic glucocorticoid 11 beta,17 beta-dihydroxy-6-methyl-17 alpha (1-propynyl)-androsta-1,4,6-trione-3-one (RU 28362). In-vitro autoradiography and quantitative image analysis showed that the type-I receptor was localized almost exclusively in the hippocampus, whereas the type-II receptor extended throughout the brain, with the highest levels in the nucleus paraventricularis, nucleus supraopticus and in the thalamic, amygdaloid, hippocampal and septal regions. Unoccupied type-I and type-II receptor sites, as measured in vitro by cytosol binding of 3H-labelled steroids, displayed a large difference in the rate of appearance after adrenalectomy. The availability of type-I receptors exhibited a marked increase, reaching maximal levels within 4-7 h, and then remained constant until 2 weeks after adrenalectomy. The availability of type-II receptors did not change considerably during the first 24 h after adrenalectomy, but displayed a large increase in capacity during the subsequent 2 weeks. After adrenocortical activation as a consequence of exposure to a novel environment, plasma concentrations of corticosterone increased to reach a peak of 811 nmol/l after 30 min and attained the basal concentration (43 nmol/l) after 240 min. During this time, occupation of type-I receptors increased from 77.8% at 0 min to 97% at 30-60 min and then declined to 84.8% after 240 min. Occupation of the type-II receptors was 28.1% at 0 min, 74.5% after 30 min and 32.8% after 240 min.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:3443807pubmed:languageenglld:pubmed
pubmed-article:3443807pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3443807pubmed:citationSubsetIMlld:pubmed
pubmed-article:3443807pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3443807pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3443807pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3443807pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3443807pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3443807pubmed:statusMEDLINElld:pubmed
pubmed-article:3443807pubmed:monthDeclld:pubmed
pubmed-article:3443807pubmed:issn0022-0795lld:pubmed
pubmed-article:3443807pubmed:authorpubmed-author:de KloetE RERlld:pubmed
pubmed-article:3443807pubmed:authorpubmed-author:SOLTM LMLlld:pubmed
pubmed-article:3443807pubmed:authorpubmed-author:van den...lld:pubmed
pubmed-article:3443807pubmed:issnTypePrintlld:pubmed
pubmed-article:3443807pubmed:volume115lld:pubmed
pubmed-article:3443807pubmed:ownerNLMlld:pubmed
pubmed-article:3443807pubmed:authorsCompleteYlld:pubmed
pubmed-article:3443807pubmed:pagination459-67lld:pubmed
pubmed-article:3443807pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:3443807pubmed:meshHeadingpubmed-meshheading:3443807-...lld:pubmed
pubmed-article:3443807pubmed:meshHeadingpubmed-meshheading:3443807-...lld:pubmed
pubmed-article:3443807pubmed:meshHeadingpubmed-meshheading:3443807-...lld:pubmed
pubmed-article:3443807pubmed:meshHeadingpubmed-meshheading:3443807-...lld:pubmed
pubmed-article:3443807pubmed:meshHeadingpubmed-meshheading:3443807-...lld:pubmed
pubmed-article:3443807pubmed:meshHeadingpubmed-meshheading:3443807-...lld:pubmed
pubmed-article:3443807pubmed:meshHeadingpubmed-meshheading:3443807-...lld:pubmed
pubmed-article:3443807pubmed:meshHeadingpubmed-meshheading:3443807-...lld:pubmed
pubmed-article:3443807pubmed:meshHeadingpubmed-meshheading:3443807-...lld:pubmed
pubmed-article:3443807pubmed:meshHeadingpubmed-meshheading:3443807-...lld:pubmed
pubmed-article:3443807pubmed:meshHeadingpubmed-meshheading:3443807-...lld:pubmed
pubmed-article:3443807pubmed:year1987lld:pubmed
pubmed-article:3443807pubmed:articleTitleRelative occupation of type-I and type-II corticosteroid receptors in rat brain following stress and dexamethasone treatment: functional implications.lld:pubmed
pubmed-article:3443807pubmed:affiliationRudolf Magnus Institute for Pharmacology, Medical Faculty, University of Utrecht, The Netherlands.lld:pubmed
pubmed-article:3443807pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3443807pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3443807lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3443807lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3443807lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3443807lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3443807lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3443807lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3443807lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3443807lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3443807lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3443807lld:pubmed